MOA: selective mTORC1 inhibitor
Tx Area: Dermatology
In skin, TORC1 plays a key role in skin barrier function, neurovascular sensitivity, sebaceous and follicular activity, and immune modulation. Rapalogix is developing a family of chemically novel TORC1 inhibitors positioned to address multiple drivers of chronic skin disorders beyond just inflammation.
Our lead program is RLX-202—a highly selective TORC1 inhibitor engineered for optimal skin penetration and targeted activity. RLX-202 is in development for chronic skin diseases with underlying TORC1 dysfunction.
Our professional skincare line is powered by our proprietary technology RLX-201—a cosmetic longevity molecule designed to reset skin’s cellular balance for long-term health and resilience.
Our first product represents a new class of pro-longevity professional skincare. Formulated to calm overactive pathways and support skin renewal, RLX-201 delivers visible results at the surface and measurable changes at the cellular level.
Re-Q HealthTM Pro-Longevity Skincare Coming Soon!
In collaboration with innovators in AI-powered skin analysis and molecular diagnostics, Rapalogix is developing next-generation tools to assess skin health. In combination, these technologies will deliver a comprehensive view of skin function, age, and resilience over time.
Currently in clinical testing alongside our cosmetic product, these platforms represent the next leap forward in pro-longevity care.
In collaboration with innovators in AI-powered skin analysis and molecular diagnostics, Rapalogix is developing next-generation tools to assess skin health. In combination, these technologies will deliver a comprehensive view of skin function, age, and resilience over time.
Currently in clinical testing alongside our cosmetic product, these platforms represent the next leap forward in pro-longevity care.